1 |
Zhou GP, Jiang YZ, Sun LY, Zhu ZJ. Protective effect of low-dose aspirin against acute cellular allograft rejection after primary liver transplantation. Liver Transpl 2023;29:E3-4. [PMID: 36746180 DOI: 10.1097/LVT.0000000000000093] [Reference Citation Analysis]
|
2 |
Oberkofler CE, Raptis DA, Petrowsky H. Reply. Liver Transpl 2023;29:E5. [PMID: 36847127 DOI: 10.1097/LVT.0000000000000094] [Reference Citation Analysis]
|
3 |
Wang J, Wu J, He Z, Xin H. Letter: PCSK9 inhibitor for liver transplant patients during the post-statin era? Aliment Pharmacol Ther 2023;57:185-6. [PMID: 36480716 DOI: 10.1111/apt.17258] [Reference Citation Analysis]
|
4 |
Becchetti C, Dirchwolf M, Berzigotti A, Bosch J. Letter: PCSK9 inhibitor for liver transplant patients during the post-statin era? Authors' reply. Aliment Pharmacol Ther 2023;57:187-8. [PMID: 36480715 DOI: 10.1111/apt.17295] [Reference Citation Analysis]
|
5 |
Zhou GP, Jiang YZ, Sun LY, Zhu ZJ. Letter: what explains improved survival from statin exposure after liver transplantation? Aliment Pharmacol Ther 2022;56:1507-8. [PMID: 36271478 DOI: 10.1111/apt.17228] [Reference Citation Analysis]
|
6 |
Becchetti C, Dirchwolf M, Schropp J, Berzigotti A, Bosch J. Letter: what explains improved survival from statin exposure after liver transplantation? Authors' reply. Aliment Pharmacol Ther 2022;56:1509-10. [PMID: 36271472 DOI: 10.1111/apt.17245] [Reference Citation Analysis]
|